COMBINE (Acamprosate/Naltrexone)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,375

Participants

Timeline

Start Date

August 31, 1997

Study Completion Date

May 31, 2006

Conditions
Alcoholism
Interventions
DRUG

naltrexone (Revia)

DRUG

acamprosate (Campral)

Trial Locations (12)

19104

Treatment and Research Center, University of Pennsylvania, Philadelphia

29425

Center for Alcohol Programs, Medical University of South Carolina, Charleston

33136

University of Miami School of Medicine, Miami

53233

University of Wisconsin-Milwaukee, Milwaukee

78229

Southwest Texas Addiction Research and Technology Center, University of Texas Health Science Center, San Antonio

87106

Center on Alcoholism, Substance Abuse and Addiction, University of New Mexico, Albuquerque

98108

Addictions Treatment Center, University of Washington, Seattle

06511

Substance Abuse Treatment Unit, Yale University, New Haven

02478

Harvard University/McLean Hospital, Belmont

02114

Massachusetts General Hospital, Boston

02118

Boston University School of Medicine, Boston

02908

Roger Williams Medical Center , Brown University, Providence

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

collaborator

Lipha Pharmaceuticals

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER

NCT00006206 - COMBINE (Acamprosate/Naltrexone) | Biotech Hunter | Biotech Hunter